An Update in the Use of Antibodies to Treat Glioblastoma Multiforme
Open Access
- 5 November 2013
- journal article
- review article
- Published by Hindawi Limited in Autoimmune Diseases
- Vol. 2013, 1-14
- https://doi.org/10.1155/2013/716813
Abstract
Glioblastoma is a deadly brain disease and modest improvement in survival has been made. At initial diagnosis, treatment consists of maximum safe surgical resection, followed by temozolomide and chemoirradiation or adjuvant temozolomide alone. However, these treatments do not improve the prognosis and survival of patients. New treatment strategies are being sought according to the biology of tumors. The epidermal growth factor receptor has been considered as the hallmark in glioma tumors; thereby, some antibodies have been designed to bind to this receptor and block the downstream signaling pathways. Also, it is known that vascularization plays an important role in supplying new vessels to the tumor; therefore, new therapy has been guided to inhibit angiogenic growth factors in order to limit tumor growth. An innovative strategy in the treatment of glial tumors is the use of toxins produced by bacteria, which may be coupled to specific carrier-ligands and used for tumoral targeting. These carrier-ligands provide tumor-selective properties by the recognition of a cell-surface receptor on the tumor cells and promote their binding of the toxin-carrier complex prior to entry into the cell. Here, we reviewed some strategies to improve the management and treatment of glioblastoma and focused on the use of antibodies.Keywords
Funding Information
- National Council of Science and Technology of Mexico (180851)
This publication has 118 references indexed in Scilit:
- E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasionBMC Cancer, 2011
- Sorafenib exerts anti-glioma activity in vitro and in vivoNeuroscience Letters, 2010
- Monoclonal antibodies: versatile platforms for cancer immunotherapyNature Reviews Immunology, 2010
- Sorafenib Induces Growth Arrest and Apoptosis of Human Glioblastoma Cells through the Dephosphorylation of Signal Transducers and Activators of Transcription 3Molecular Cancer Therapeutics, 2010
- Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02)Neuro-Oncology, 2010
- Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant gliomaCancer, 2009
- The Contributions of Paul Ehrlich to Pharmacology: A Tribute on the Occasion of the Centenary of His Nobel PrizePharmacology, 2008
- AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma PatientsCancer Cell, 2007
- Immunotoxin therapy of cancerNature Reviews Cancer, 2006
- Patterns and Emerging Mechanisms of the Angiogenic Switch during TumorigenesisCell, 1996